



ARSEUS IPO Early closing of the Offering

Waregem (Belgium), October 2, 2007 - Arseus NV, the professional healthcare division of Omega Pharma, today announces the early closing of its initial public offering.

The number of Shares subscribed to since the commencement of the Offering Period substantially exceeded the number of Shares Offered. The Offering Period was therefore closed early on October 2, 2007 at 4PM CET, as outlined in the Prospectus.

The key dates for the transaction going forward are the following:

- **October 5, 2007:** Publication of the results of the Offering, the priority allocation ratio, the allocation key for retail investors and the Offer Price in the Belgian financial press as well as on the websites of Arseus and Omega Pharma.
- **October 5, 2007:** Start of conditional trading of the Shares, VVPR strips and Offering Warrants on Eurolist by Euronext Brussels and/or Amsterdam.
- **October 9, 2007:** Payment and settlement of the Shares and the capital increase.

The Offering comprised a public offering in Belgium and a private placement to institutional investors in Belgium, as well as elsewhere in the European Economic Area and Switzerland in reliance on Regulation S under the US Securities Act of 1933. The Offering included a total of up to 17,500,000 Existing Shares and of up to 6,000,000 New Shares (with VVPR strips attached) of Arseus NV. Furthermore, Omega Pharma NV has granted the Joint Global Coordinators an Over-allotment Option of up to an additional 2,968,144 Existing Shares.

Arseus profile

Arseus generated a turnover of € 277 million in 2006, with 1,230 staff members. Arseus supplies healthcare professionals, on a European level, with products and services that enable them to provide high-quality services in an efficient manner. Arseus services pharmacists, general practitioners, specialist physicians, dentists, eye care professionals, nursing staff as well as hospitals and elderly care homes. Ageing population and the growing consumer awareness for health, well-being and aesthetics lead to a strong growth market for Arseus.

For more information, please contact:

Arseus

Ger van Jeveren, Chief Executive Officer

Tel: +32 56 62 88 00

Jan Peeters, Chief Financial Officer

Omega Pharma

Chris Van Raemdonck

Tel: +32 9 381 03 31

The Offering and the distribution of the Prospectus and this press release may be restricted by law in certain jurisdictions outside Belgium. Arseus does not represent that the Prospectus or this press release may be lawfully distributed in jurisdictions outside Belgium or that the Shares, VVPR strips or Offering Warrants may be lawfully offered in compliance with any applicable registration or other requirements in jurisdictions outside Belgium, or pursuant to any exemption available thereunder. Arseus does not assume any responsibility for such distribution or offering. Accordingly, the Shares, VVPR Strips or Offering Warrants may not be offered or sold, directly or indirectly, and neither the Prospectus, this press release nor any advertising or other offering materials may be distributed or published in any jurisdiction outside Belgium, except in circumstances that will result in compliance with any applicable laws and regulations. The Prospectus does not constitute an offer to sell or a solicitation of an offer to buy any of the securities to any person in any jurisdiction in which it is unlawful to make such offer or solicitation to such person. Persons in whose possession the Prospectus or any of the securities come, must inform themselves about, and observe any such restrictions.

The Offered Shares have not been and will not be registered under the Securities Act of the USA. Subject to certain exceptions, the securities may not be offered, sold or delivered in the United States of America (USA), or to, for the account or benefit of, US persons, except in certain transactions exempt from the registration requirements of the Securities Act. The terms used in this paragraph have the meanings given to them by Regulation S. The Shares, VVPR Strips and Offering Warrants have not been approved or disapproved by the USA Securities and Exchange Commission, any state securities commission in the USA or any other USA regulatory authority, nor have any of the foregoing authorities passed upon or endorsed the merits of the securities or the accuracy or adequacy of the Prospectus. Any representation to the contrary is a criminal offence in the USA.